查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924669

胃腸道標記膠囊市場按技術、年齡層、應用、最終用戶和分銷管道分類－2026-2032年全球預測

Gastrointestinal Marker Capsule Market by Technology, Age Group, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年胃腸道標記膠囊市值為 3.5117 億美元，預計到 2026 年將成長至 3.9656 億美元，年複合成長率為 12.36%，到 ​​2032 年將達到 7.9403 億美元。

關鍵市場統計數據
基準年 2025 3.5117億美元
預計年份：2026年 3.9656億美元
預測年份 2032 7.9403億美元
複合年成長率 (%) 12.36%

本書簡明扼要、權威地概述了基於膠囊的胃腸道診斷技術如何重新定義醫療保健環境中的臨床路徑和患者選擇。

胃腸道標記膠囊已成為胃腸道診斷領域的一項重要創新，它是一種微創選擇，可作為內視鏡和放射學檢查的補充。隨著技術的進步，影像解析度不斷提高，感測器體積越來越小，與臨床工作流程的整合也越來越緊密，膠囊正從一種小眾臨床工具轉變為更廣泛應用的輔助診斷手段。臨床醫師和醫療系統領導者正日益重視膠囊診斷如何簡化病患診療流程、減輕檢查負擔，並擴大傳統醫院環境以外的篩檢和監測範圍。

檢驗技術、臨床和醫療保健系統領域的融合力量如何推動胃腸道膠囊診斷的快速變化。

技術、臨床實踐和醫療保健系統優先事項的整合正在推動胃腸道標記膠囊領域變革性轉變。感測器性能和數據處理技術的進步使膠囊能夠收集更精確的生理和視覺訊息，而新型推進和定位技術則拓展了膠囊的臨床應用場景。同時，與數位健康平台和機器學習分析的整合為自動病灶檢測、縱向監測和遠距離診斷工作流程帶來了新的可能性，從而減少了對現場操作和專家資源的依賴。

分析新貿易關稅對胃腸診斷價值鏈中採購、價格波動和韌性策略的連鎖影響

2025年推出的新關稅和貿易措施對胃腸道標記膠囊生產商和經銷商的供應鏈、籌資策略和競爭地位產生了多方面的影響。關稅變化正在影響零件和成品的到岸成本，迫使各企業重新評估其籌資策略和供應商關係。為此，許多相關人員正在加快供應商多元化，探索近岸外包方案，並重新談判契約，以降低進口關稅上漲和物流複雜性的風險。

深度細分分析揭示了臨床適應症、給藥地點、技術選擇、分銷策略和患者人口統計特徵如何影響產品採用路徑。

要了解市場，需要對臨床應用、臨床環境、設備技術、分銷機制和患者族群特徵有深入的了解，因為這些因素都會影響產品設計、推廣障礙和商業性重點。應用層級的差異化範圍很廣，從結腸的結直腸癌篩檢和發炎性腸道疾病監測，到食道的巴瑞特氏食道症和食道癌監測，再到小腸的克隆氏症和不明原因消化道出血，以及胃癌篩檢和胃輕癱的治療。這些不同的臨床適應症有不同的證據要求、臨床醫生工作流程和患者期望，這些都會影響設備的影像方式、傳輸控制和診斷演算法等功能。

區域市場動態和策略需求凸顯了地域差異將如何驅動產品應用、監管路徑和分銷策略。

區域趨勢對臨床應用、報銷政策、監管時間表和分銷基礎設施都具有深遠的影響。有效的策略必須充分考慮地域差異。在美洲，臨床實踐模式和支付方環境為篩檢和門診監測領域的應用創造了機會。然而，醫療服務模式的地域差異意味著商業化策略必須針對每個次區域和醫療環境進行客製化。支付結構以及對基於價值的醫療結果日益成長的關注，正促使相關人員展示臨床獲益和營運效率，以支持更廣泛的應用。

競爭與合作並重的企業策略，優先考慮臨床證據、技術差異化和整合商業化模式

胃腸道標記膠囊領域的競爭格局由成熟的醫療設備製造商、新興的專業開發商以及將硬體與先進分析技術相結合的技術整合商組成。主要企業透過專有的成像感測器、微型電子元件、更長的電池續航時間以及磁控和增強定位等輔助技術的應用來脫穎而出。同樣重要的是，企業能夠透過同行評審的研究和真實世界數據來證明其臨床效用，這構成了臨床醫生信心和支付方評估的基礎。

領導者可採取切實可行的策略重點，協調臨床檢驗、供應鏈韌性和差異化商業化，以實現可擴展的應用。

尋求擴大應用範圍並打造永續競爭優勢的產業領導者應採取多管齊下的策略，整合臨床療效檢驗、供應鏈韌性和卓越的商業化能力。首先，優先考慮針對特定適應症（例如結直腸癌篩檢、發炎性疾病監測和小腸出血檢測）的高品質臨床證據，將有助於加快與臨床實踐指南的銜接，並獲得支付方的認可。同時，加強對互通性、數據分析以及與電子健康記錄無縫整合的投入，將增強診斷價值提案，並支援工作流程的最佳化。

採用穩健的混合調查方法，結合相關人員訪談、臨床文獻綜合和情境分析，以得出可操作的研究結果。

本研究採用兼顧臨床嚴謹性和商業性實用性的調查方法，整合一手和二手證據，對胃腸道標誌膠囊進行全面分析。一級資訊來源包括對胃腸病學各專科臨床醫生、醫院和門診中心採購主管以及醫療設備製造和分銷企業高管的結構化訪談。此外，本研究還系統性回顧了同儕審查的臨床研究、監管申報文件和行業白皮書，以闡明其臨床效用和證據缺口。

關於臨床可接受性、營運重點和策略屬性的共識，這些因素共同促成了胃腸道診斷領域的持續成功。

未來胃腸道標誌膠囊的發展趨勢將是穩步向非侵入性診斷技術轉型，優先考慮患者體驗、臨床效率和可擴展的解讀模型。持續的技術改進、策略性的證據累積以及適應性的商業化策略，將決定哪些平台能夠被廣泛整合到臨床實踐中。醫療系統和臨床醫生將尋求能夠減輕檢測負擔、同時保持或提高診斷準確性的診斷技術，而那些能夠實際改善工作流程的技術將獲得最多的支援。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的胃腸道標記膠囊市場

  • 磁性膠囊
  • 無線膠囊

9. 按年齡層別分類的胃腸道標記膠囊市場

  • 成人版
  • 老年人
  • 兒童

第10章 胃腸道標記膠囊市場（按應用領域分類）

  • 冒號
    • 大腸癌篩檢
    • 監測發炎性腸道疾病
  • 食道
    • 巴瑞特氏食道症
    • 食道癌
  • 小腸
    • 克隆氏症
    • 不明原因的消化道出血
  • 胃
    • 胃癌篩檢
    • 胃輕癱

第11章 胃腸道標記膠囊市場（按最終用戶分類）

  • 門診手術中心
  • 診所
  • 診斷中心
  • 醫院

第12章 胃腸道標記膠囊市場（依分銷管道分類）

  • 離線
  • 線上

第13章 各地區胃腸道標記膠囊市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 胃腸道標記膠囊市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國胃腸道標記膠囊市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國胃腸道標記膠囊市場

第17章：中國胃腸道標誌膠囊市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ankon Technologies Co., Ltd.
  • AnX Robotica, Inc.
  • Atmo Biosciences, Inc.
  • BodyCap SAS
  • CapsoMed, Inc.
  • CapsoVision, Inc.
  • Chongqing Jinshan Science & Technology Co., Ltd.
  • Covidien Ltd.
  • EndoChoice, Inc.
  • GI View Ltd.
  • Given Imaging Ltd.
  • Heidelberg Medical GmbH
  • HQ, Inc.
  • Hughes Medical Systems Ltd.
  • IntroMedic Co., Ltd.
  • Intromedic Co., Ltd.
  • Jinshan Science & Technology Co., Ltd.
  • Medtronic plc
  • Olympus Corporation
  • RFID Global, Inc.
Product Code: MRR-7A380DA7C412

The Gastrointestinal Marker Capsule Market was valued at USD 351.17 million in 2025 and is projected to grow to USD 396.56 million in 2026, with a CAGR of 12.36%, reaching USD 794.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 351.17 million
Estimated Year [2026] USD 396.56 million
Forecast Year [2032] USD 794.03 million
CAGR (%) 12.36%

A concise and authoritative overview of how capsule-based gastrointestinal diagnostics are redefining clinical pathways and patient preferences across care settings

The gastrointestinal marker capsule has emerged as a pivotal innovation in the continuum of GI diagnostics, offering a minimally invasive option that complements endoscopic and radiologic modalities. As technology has advanced, the capsule has transitioned from a niche clinical tool to a more broadly considered diagnostic adjunct, driven by improvements in imaging resolution, sensor miniaturization, and integration with clinical workflows. Clinicians and health system leaders are increasingly evaluating how capsule-based diagnostics can streamline patient pathways, reduce procedural burden, and expand access to screening and monitoring outside traditional hospital settings.

In addition, the evolving clinical landscape has brought renewed attention to patient-centric diagnostics. Patients often prefer less invasive alternatives that offer convenience and reduced recovery time, and this preference is shaping adoption patterns across multiple specialties. Coupled with these demand drivers, regulatory agencies and payers are scrutinizing evidence bundles that demonstrate clinical utility and cost-effectiveness. Consequently, manufacturers, clinical investigators, and procurement teams must align product development, evidence generation, and commercialization strategies to bridge the gap between promising technology and routine clinical use. This introduction sets the stage for a deeper examination of transformative shifts, policy impacts, segmentation intelligence, regional dynamics, and strategic recommendations that follow.

Examining the converging technological, clinical, and health system forces that are driving rapid transformation in gastrointestinal capsule diagnostics

The landscape for gastrointestinal marker capsules is undergoing transformative shifts driven by converging forces in technology, clinical practice, and health system priorities. Advances in sensor capabilities and data processing are enabling capsules to capture higher fidelity physiologic and visual information, while novel propulsion and localization techniques are expanding the clinical scenarios in which capsules can be deployed. Concurrently, integration with digital health platforms and machine learning analytics is creating new possibilities for automated lesion detection, longitudinal monitoring, and remote interpretation workflows, thereby reducing reliance on in-person procedures and specialist availability.

Beyond the technological frontier, clinical guidelines and care pathways are evolving to reflect evidence supporting non-invasive or minimally invasive approaches in screening and disease monitoring. Health systems are focused on capacity optimization, and as a result, ambulatory and outpatient settings are receiving greater attention as viable venues for diagnostic services. Reimbursement models and value-based care initiatives are prompting stakeholders to assess diagnostics through the lens of patient outcomes and downstream cost implications. In short, the combined momentum of technological innovation, digital enablement, and health economics is reshaping how gastrointestinal marker capsules are perceived and deployed within modern healthcare delivery.

Analyzing the cascading effects of new trade tariffs on sourcing, pricing dynamics, and resilience strategies across the gastrointestinal diagnostics value chain

The introduction of new tariffs and trade measures in 2025 has introduced multifaceted effects across supply chains, procurement strategies, and competitive positioning for manufacturers and distributors of gastrointestinal marker capsules. Tariff changes influence the landed cost of components and finished devices, prompting organizations to reassess sourcing strategies and supplier relationships. In response, many stakeholders are accelerating supplier diversification, exploring nearshoring options, and renegotiating contracts to mitigate exposure to elevated import duties and logistical complexities.

At the same time, tariff-driven cost pressure can accelerate innovation in local manufacturing and assembly, as stakeholders seek to maintain price competitiveness while protecting margins. This transition often requires investment in quality systems, regulatory alignment, and workforce development to meet clinical-grade manufacturing standards. Moreover, payers and providers may scrutinize procurement decisions more closely when device costs are impacted by trade policy, making demonstrable clinical value and operational efficiency paramount. Ultimately, the cumulative impact of tariffs in 2025 is less a single disruptive event than a catalyst for strategic realignment across the value chain, prompting a shift toward resilient sourcing, closer supplier partnerships, and strengthened value propositions that justify procurement decisions under new cost structures.

Deep segmentation intelligence revealing how clinical indications, care venues, technology choices, distribution strategies, and patient age cohorts shape adoption pathways

Understanding the market requires a nuanced view of clinical applications, care settings, device technologies, distribution mechanisms, and patient demographics, because each axis influences product design, adoption barriers, and commercial prioritization. Application-level differentiation ranges from colorectal cancer screening and inflammatory bowel disease monitoring in the colon to Barrett's esophagus and esophageal cancer surveillance in the esophagus, extending to Crohn's disease and obscure gastrointestinal bleeding in the small intestine, and to gastric cancer screening and gastroparesis management in the stomach. These distinct clinical indications carry varied evidence requirements, clinician workflows, and patient expectations, which in turn shape device features such as imaging modalities, transit control, and diagnostic algorithms.

End-user segmentation further refines commercial approaches as adoption patterns differ across ambulatory surgery centers, outpatient clinics, diagnostic centers, and hospitals. Each setting presents unique operational constraints, regulatory considerations, and throughput imperatives that inform sales strategies and support models. Technology choices, notably between magnetic capsule systems that offer active locomotion or enhanced positioning and wireless capsule platforms that emphasize passive transit and ease of administration, influence training needs and clinical utility. Distribution channel selection, whether through direct sales models that provide hands-on training and service, distributor partnerships that offer broader geographic reach, or online sales that prioritize convenience and scale, affects market access and customer experience. Finally, patient age groups-adult, geriatric, and pediatric populations-introduce clinical and ergonomic requirements that impact capsule size, imaging parameters, and interpretation frameworks. Together, these segmentation dimensions create a complex mosaic that companies must navigate to align product attributes, evidence generation, and commercial execution with clinical realities.

Regional market dynamics and strategic imperatives highlighting how geographic nuances drive adoption, regulatory pathways, and distribution strategies

Regional dynamics exert a profound influence on clinical adoption, reimbursement policy, regulatory timelines, and distribution infrastructure, and an effective strategy must be attuned to geographic nuances. In the Americas, clinical practice patterns and payer landscapes create opportunities for adoption in both screening and ambulatory monitoring contexts, yet geographic heterogeneity in healthcare delivery models means that commercialization strategies must be tailored by subregion and care setting. Payment structures and the emphasis on value-based outcomes encourage stakeholders to substantiate clinical benefits and operational efficiencies to support wider uptake.

In Europe, Middle East & Africa, regulatory harmonization and cross-border distribution considerations present both opportunities and obstacles. Many markets in this region maintain rigorous clinical evidence requirements and centralized reimbursement pathways, while others present opportunities for early adoption based on unmet clinical needs and concentrated centers of excellence. Building local partnerships and navigating country-specific regulatory frameworks are essential to establishing trust with clinical communities. In Asia-Pacific, rapid modernization of healthcare infrastructure, aggressive screening initiatives, and a large population base create fertile ground for scale, but market entry often demands localization of clinical validation, supply chain flexibility, and sensitivity to diverse payer models. Across all regions, adapting to local clinical workflows, forging key clinical partnerships, and aligning pricing and reimbursement strategies are central to unlocking adoption and long-term sustainability.

Competitive and collaborative company strategies that prioritize clinical evidence, technological differentiation, and integrated commercialization models

Competitive dynamics in the gastrointestinal marker capsule space are shaped by a mix of established medical device firms, emerging specialized developers, and technology integrators that combine hardware with advanced analytics. Leading players differentiate through proprietary imaging sensors, miniaturized electronics, improved battery life, and the incorporation of adjunct technologies such as magnetic control or enhanced localization. Equally important is the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence, which informs clinician trust and payer assessments.

Strategic collaborations are increasingly common as companies seek to bundle diagnostics with interpretation services, cloud-based analytics, or supplemental devices that extend clinical capabilities. Partnerships with clinical centers of excellence not only accelerate evidence generation but also provide critical feedback loops for product iteration. Additionally, distribution partnerships-whether through specialized medical distributors or integrated health network agreements-play a decisive role in market penetration. As competition intensifies, companies that pair technical differentiation with robust clinician education programs, accessible support services, and compelling health-economic narratives are better positioned to capture long-term clinical adoption and institutional buy-in.

Actionable strategic priorities for leaders to align clinical validation, supply chain resilience, and differentiated commercialization for scalable adoption

Industry leaders seeking to scale adoption and create sustainable competitive advantage should pursue a multi-dimensional strategy that aligns clinical validation, supply chain resilience, and commercialization excellence. First, prioritizing high-quality clinical evidence tailored to specific indications-such as colorectal screening, inflammatory disease monitoring, or small intestine bleeding detection-will accelerate guideline alignment and payer recognition. Concurrently, investing in interoperability, data analytics, and seamless integration with electronic health records enhances the diagnostic value proposition and supports workflow adoption.

Operationally, diversifying manufacturing footprints and strengthening supplier relationships will mitigate exposure to trade policy shifts and logistical disruptions. Strategic engagement with ambulatory and outpatient care providers can unlock new pathways for decentralized diagnostics, while education programs directed at clinicians and care coordinators reduce adoption friction. Commercially, tailoring go-to-market approaches to the distribution channel-providing direct clinical support where necessary, leveraging distributor networks for geographic reach, and using online channels for lower-friction transactions-will optimize coverage across settings. Finally, adopting a patient-centered design approach that accommodates adult, geriatric, and pediatric needs will broaden market relevance and support value-based conversations with providers and payers.

Robust mixed-methods research approach combining stakeholder interviews, clinical literature synthesis, and scenario analysis to produce actionable insights

This research synthesizes primary and secondary evidence to build a comprehensive view of the gastrointestinal marker capsule landscape, employing a methodology that balances clinical rigor with commercial applicability. Primary inputs include structured interviews with clinicians across gastroenterology subspecialties, procurement leaders in hospitals and outpatient centers, and senior executives across device manufacturing and distribution. These qualitative insights are complemented by a systematic review of peer-reviewed clinical studies, regulatory filings, and industry white papers to contextualize clinical utility and evidence gaps.

Analytical techniques include comparative feature mapping of platform capabilities, scenario analysis for supply chain resilience under varying trade conditions, and stakeholder mapping across end users and distribution channels. Where applicable, the methodology emphasizes triangulation of findings-corroborating clinician perspectives with published clinical outcomes and regulatory status-to ensure robust conclusions. The research also incorporates regional regulatory and reimbursement landscape scans to illuminate market-entry considerations. Throughout, emphasis is placed on transparent assumptions, documented limitations, and clear delineation between observed trends and strategic implications to support informed decision-making.

Convergent conclusions on clinical acceptance, operational priorities, and the strategic attributes that enable durable success in gastrointestinal diagnostics

The trajectory for gastrointestinal marker capsules is characterized by a steady shift toward non-invasive diagnostics that prioritize patient experience, clinical efficiency, and scalable interpretation models. Continued technological refinement, coupled with strategic evidence generation and adaptive commercialization approaches, will determine which platforms achieve widespread clinical integration. Health systems and clinicians seek diagnostics that reduce procedural burden while preserving or enhancing diagnostic accuracy, and technologies that demonstrate tangible workflow benefits will attract the greatest support.

Looking ahead, successful adoption will hinge on aligning product capabilities with clinical needs, building robust evidence tailored to distinct indications, and structuring commercial models that reflect the realities of diverse care settings and regional reimbursement frameworks. Additionally, resilience in supply chains and agility in response to policy shifts will remain essential. Ultimately, companies that combine clinical credibility, operational excellence, and patient-centered design thinking are best positioned to drive meaningful impact in gastrointestinal diagnostics and to contribute to more accessible, efficient, and evidence-based care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Marker Capsule Market, by Technology

  • 8.1. Magnetic Capsule
  • 8.2. Wireless Capsule

9. Gastrointestinal Marker Capsule Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Gastrointestinal Marker Capsule Market, by Application

  • 10.1. Colon
    • 10.1.1. Colorectal Cancer Screening
    • 10.1.2. Ibd Monitoring
  • 10.2. Esophagus
    • 10.2.1. Barrett's Esophagus
    • 10.2.2. Esophageal Cancer
  • 10.3. Small Intestine
    • 10.3.1. Crohn's Disease
    • 10.3.2. Obscure Gi Bleeding
  • 10.4. Stomach
    • 10.4.1. Gastric Cancer Screening
    • 10.4.2. Gastroparesis

11. Gastrointestinal Marker Capsule Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
  • 11.3. Diagnostic Centers
  • 11.4. Hospitals

12. Gastrointestinal Marker Capsule Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Gastrointestinal Marker Capsule Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastrointestinal Marker Capsule Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastrointestinal Marker Capsule Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastrointestinal Marker Capsule Market

17. China Gastrointestinal Marker Capsule Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ankon Technologies Co., Ltd.
  • 18.6. AnX Robotica, Inc.
  • 18.7. Atmo Biosciences, Inc.
  • 18.8. BodyCap SAS
  • 18.9. CapsoMed, Inc.
  • 18.10. CapsoVision, Inc.
  • 18.11. Chongqing Jinshan Science & Technology Co., Ltd.
  • 18.12. Covidien Ltd.
  • 18.13. EndoChoice, Inc.
  • 18.14. GI View Ltd.
  • 18.15. Given Imaging Ltd.
  • 18.16. Heidelberg Medical GmbH
  • 18.17. HQ, Inc.
  • 18.18. Hughes Medical Systems Ltd.
  • 18.19. IntroMedic Co., Ltd.
  • 18.20. Intromedic Co., Ltd.
  • 18.21. Jinshan Science & Technology Co., Ltd.
  • 18.22. Medtronic plc
  • 18.23. Olympus Corporation
  • 18.24. RFID Global, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 177. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 180. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 207. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 217. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 220. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)